Reckitt Benckiser Group’s (RB) Buy Rating Reiterated at JPMorgan Chase & Co.
JPMorgan Chase & Co. restated their buy rating on shares of Reckitt Benckiser Group (LON:RB) in a report published on Monday morning, Borsen Zeitung reports. They currently have a GBX 6,500 ($85.50) target price on the stock.
Several other research firms have also recently weighed in on RB. Citigroup restated a buy rating on shares of Reckitt Benckiser Group in a research note on Wednesday, March 11th. Berenberg Bank restated a buy rating and issued a GBX 7,150 ($94.05) price target on shares of Reckitt Benckiser Group in a research note on Friday, February 28th. Royal Bank of Canada boosted their price target on Reckitt Benckiser Group from GBX 5,000 ($65.77) to GBX 5,300 ($69.72) and gave the stock an underperform rating in a research note on Monday. Goldman Sachs Group boosted their price target on Reckitt Benckiser Group from GBX 5,800 ($76.30) to GBX 6,000 ($78.93) and gave the stock a neutral rating in a research note on Tuesday, March 17th. Finally, Morgan Stanley restated a buy rating and issued a GBX 6,600 ($86.82) price target on shares of Reckitt Benckiser Group in a research note on Monday, March 16th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and eleven have issued a buy rating to the company. Reckitt Benckiser Group presently has a consensus rating of Hold and a consensus target price of GBX 6,386.58 ($84.01).
RB stock opened at GBX 5,700 ($74.98) on Monday. Reckitt Benckiser Group has a 1-year low of GBX 5,130 ($67.48) and a 1-year high of GBX 8,191.30 ($107.75). The business has a fifty day moving average price of GBX 6,063.10 and a 200-day moving average price of GBX 6,097.08. The company has a debt-to-equity ratio of 130.80, a current ratio of 0.56 and a quick ratio of 0.41. The stock has a market capitalization of $40.88 billion and a P/E ratio of -10.97.
In related news, insider Laxman Narasimhan sold 14,718 shares of Reckitt Benckiser Group stock in a transaction on Monday, March 23rd. The stock was sold at an average price of GBX 5,833 ($76.73), for a total value of £858,500.94 ($1,129,309.31).
About Reckitt Benckiser Group
Reckitt Benckiser Group plc manufactures, markets, and sells health, hygiene, and home products. The company offers acne treatment creams, facial washes, and cleansing pads; disinfection, hygiene, and first aid products; condoms, sex toys, and lubricants; heartburn and indigestion solutions; and cough and chest congestion, multi-symptom, and sinus remedies for adults and children under the Clearasil, Dettol, Durex, Gaviscon, and Mucinex brands.
Receive News & Ratings for Reckitt Benckiser Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Reckitt Benckiser Group and related companies with MarketBeat.com's FREE daily email newsletter.